Dissemin is shutting down on January 1st, 2025

Published in

American Academy of Neurology (AAN), Neurology, 16(89), p. 1668-1675, 2017

DOI: 10.1212/wnl.0000000000004508

Links

Tools

Export citation

Search in Google Scholar

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Objective:To investigate the effect of chronic comorbidity on the time of diagnosis of multiple sclerosis (MS) and on mortality in MS.Methods:We conducted a population-based, nationwide cohort study including all incident MS cases in Denmark with first MS symptom between 1980 and 2005. To investigate the time of diagnosis, we compared individuals with and without chronic comorbidity using multinomial logistic regression. To investigate mortality, we used Cox regression with time-dependent covariates, following study participants from clinical MS onset until endpoint (death) or to the end of the study, censuring at emigration.Results:We identified 8,947 individuals with clinical onset of MS between 1980 and 2005. In the study of time of diagnosis, we found statistically significant odds ratios for longer diagnostic delays with cerebrovascular comorbidity (2.01 [1.44–2.80]; <0.0005), cardiovascular comorbidity (4.04 [2.78–5.87]; <0.0005), lung comorbidity (1.93 [1.42–2.62]; <0.0005), diabetes comorbidity (1.78 [1.04–3.06]; 0.035), and cancer comorbidity (2.10 [1.20–3.67]; 0.009). In the mortality study, we found higher hazard ratios with psychiatric comorbidity (2.42 [1.67–3.01]; <0.0005), cerebrovascular comorbidity (2.47 [2.05–2.79]; <0.0005), cardiovascular comorbidity (1.68 [1.39–2.03]; <0.0005), lung comorbidity (1.23 [1.01–1.50]; 0.036), diabetes comorbidity (1.39 [1.05–1.85]; 0.021), cancer comorbidity (3.51 [2.94–4.19]; <0.0005), and Parkinson disease comorbidity (2.85 [1.34–6.06]; 0.007).Conclusions:An increased awareness of both the necessity of neurologic evaluation of new neurologic symptoms in persons with preexisting chronic disease and of optimum treatment of comorbidity in MS is critical.